Cohance Lifesciences Limited (COHANCE.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-9.7%

₹396.69

vs ₹439.50 price

Levered DCF

₹532.03

After debt service

Piotroski score

6 / 9

Average

Altman Z-score

9.25

Safe zone

Rating

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	64.28×	102.78×	56.75×	29.23×	34.69×	34.91×	8.07×	16.36×
P/B	2.95×	16.2×	8.31×	6.93×	10.31×	10.71×	3.03×	7.27×
P/S	5.08×	22.94×	16.22×	8.97×	11.92×	12.53×	3.07×	4.73×
EV / EBITDA	27.48×	68.23×	41.73×	21.01×	27.24×	28.98×	7.15×	10.85×
Gross margin	40.2%	68.6%	64.7%	56.1%	56.5%	56.7%	59.9%	58.9%
Operating margin	10.6%	47.2%	51.4%	47.0%	48.0%	47.8%	49.9%	49.9%
Net margin	7.9%	22.4%	28.6%	30.7%	34.4%	35.9%	38.0%	28.9%
Current ratio	2.78×	2.43×	11.82×	6.37×	5.36×	2.57×	1.95×	2.47×
Debt / equity	0.1×	0.16×	0.03×	0.04×	0.06×	0.12×	0.22×	0.14×
Interest coverage	6.44×	45.8×	72.49×	49.2×	75.12×	42.35×	20.47×	162.36×
Dividend yield	0.0%	0.0%	0.0%	1.7%	0.6%	0.2%	3.0%	0.5%
Payout ratio	0.0%	0.0%	0.0%	49.5%	22.4%	7.0%	24.2%	8.8%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	4.6%	15.8%	14.6%	23.7%	29.7%	30.7%	37.5%	44.4%
Return on invested capital	3.3%	15.7%	18.2%	24.7%	25.5%	27.5%	30.6%	45.3%
Return on assets	3.1%	8.8%	13.3%	20.9%	24.8%	24.6%	27.0%	33.5%
Free cash flow yield	1.2%	0.5%	1.8%	1.4%	1.6%	2.2%	12.4%	-0.1%
Earnings yield	1.6%	1.0%	1.8%	3.4%	2.9%	2.9%	12.4%	6.1%
Enterprise value	₹118.6B	₹276.7B	₹170.7B	₹120.3B	₹158B	₹127.8B	₹27.3B	₹43.6B
Net debt / EBITDA	0.79×	0.48×	0.04×	0.01×	0.09×	0.31×	0.46×	0.18×
Cash conversion cycle (days)	185	171	232	225	190	154	154	163